Approval is based on the Phase 3 MAGNITUDE study, a prospectively designed precision medicine study including the largest population of BRCA-positive patients in combination trials to date with metastatic castration-resistant prostate cancer (mCRPC) AKEEGA™ plus prednisone significantly…

NEW YORK and LOS ANGELES, Aug. 11, 2023 /PRNewswire/ — Fox Corporation (Nasdaq: FOXA, FOX) today announced that Chief Legal and Policy Officer Viet Dinh will step down from his position and become a Special Advisor to the Company effective December 31, 2023. “We appreciate Viet’s many…

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.